Eyepoint Pharmaceuticals Inc (EYPT) Financials
$4.56
As on 08-Sep-2026 16:27EDT
Market cap
$384 Mln
Revenue (TTM)
$3 Mln
P/E Ratio
--
P/B Ratio
2.4
Div. Yield
0 %
Income Statement ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Operating Revenue
|
2.79
|
31.37
|
43.27
|
46.02
|
41.40
|
36.94
|
|||||
|
Cost of Revenue
|
1.62
|
2.07
|
3.71
|
4.63
|
8.33
|
8.18
|
|||||
|
Gross Profit
|
1.17
|
29.31
|
39.56
|
41.39
|
33.08
|
28.76
|
|||||
|
Operating Expenses
|
318.14
|
272.74
|
185.42
|
116.45
|
132.72
|
84.04
|
|||||
|
Operating Profit (EBIT)
|
-316.98
|
-243.43
|
-145.85
|
-75.07
|
-99.64
|
-55.28
|
|||||
|
Other Income
|
--
|
--
|
--
|
--
|
0.57
|
2.36
|
|||||
|
Profit before Tax
|
-306.51
|
-231.68
|
-130.78
|
-70.71
|
-102.25
|
-58.42
|
|||||
|
Provision for Tax
|
-0.14
|
0.28
|
0.09
|
0.08
|
22.26
|
5.50
|
|||||
|
Profit after Tax (Net Income)
|
-306.64
|
-231.96
|
-130.87
|
-70.80
|
-102.25
|
-58.42
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Consolidated Profit
|
--
|
--
|
--
|
--
|
-102.25
|
-58.42
|
Liabilities ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Shareholder's Funds
|
166.41
|
306.11
|
336.50
|
266.32
|
96.37
|
184.38
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Non-Current Liabilities
|
19.84
|
20.86
|
32.92
|
25.60
|
49.45
|
55.33
|
|||||
|
Current Liabilities
|
41.94
|
37.02
|
49.05
|
63.26
|
34.54
|
23.66
|
|||||
|
Total Liabilities
|
270.13
|
364.00
|
418.47
|
355.18
|
180.36
|
263.37
|
Assets ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Non-Current Assets
|
39.37
|
35.34
|
35.16
|
10.38
|
7.55
|
25.63
|
|||||
|
Current Assets
|
188.82
|
328.66
|
383.31
|
344.80
|
172.81
|
237.75
|
|||||
|
Total Assets
|
270.13
|
364.00
|
418.47
|
355.18
|
180.36
|
263.37
|
|||||
|
Total Debt*
|
22.37
|
22.79
|
21.86
|
4.91
|
46.35
|
39.20
|
|||||
|
Net Current Assets
|
146.87
|
291.63
|
334.26
|
281.54
|
138.27
|
214.09
|
Cashflow ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
--
|
-240.11
|
-126.23
|
1.88
|
-65.01
|
-50.10
|
|||||
|
Cash Flow from Investing Activities
|
--
|
68.58
|
-219.36
|
-3.32
|
-17.27
|
-33.12
|
|||||
|
Cash from Financing Activities
|
--
|
173.65
|
164.02
|
187.07
|
-0.69
|
216.90
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
--
|
--
|
--
|
-82.96
|
133.68
|
Financials Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
-3.74
|
-2.79
|
-2.03
|
-1.68
|
-2.74
|
-1.79
|
|||||
|
Cash EPS ($)
|
--
|
-2.77
|
-2.00
|
-1.67
|
-2.67
|
-1.70
|
|||||
|
Adjusted Book Value ($)
|
--
|
3.69
|
5.21
|
6.32
|
2.58
|
5.64
|
|||||
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share ($)
|
--
|
-2.89
|
-1.96
|
0.04
|
-1.74
|
-1.53
|
|||||
|
Free Cash Flow per Share ($)
|
--
|
-2.93
|
-2.02
|
-0.04
|
-1.80
|
-1.54
|
Profitability Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
--
|
-67.50
|
-41.57
|
-34.21
|
-55.83
|
-40.49
|
|||||
|
ROE (%)
|
-129.79
|
-72.19
|
-43.42
|
-39.04
|
-72.84
|
-57.58
|
|||||
|
ROA (%)
|
-101.46
|
-59.29
|
-33.83
|
-26.44
|
-46.09
|
-32.90
|
|||||
|
EBIT Margin (%)
|
-10,672.10
|
-738.42
|
-302.19
|
-150.95
|
-239.26
|
-143.26
|
|||||
|
Net Margin (%)
|
-10,994.73
|
-739.42
|
-302.43
|
-153.84
|
-243.60
|
-148.66
|
|||||
|
Cash Profit Margin (%)
|
0.00
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-94.63
|
-0.28
|
-0.06
|
0.11
|
0.12
|
0.07
|
|||||
|
EBIT Growth (%)
|
-69.90
|
-77.15
|
-88.25
|
29.88
|
-87.20
|
-38.76
|
|||||
|
Net Profit Growth (%)
|
-74.84
|
-77.25
|
-84.86
|
30.77
|
-75.04
|
-28.69
|
|||||
|
EPS Growth (%)
|
-39.78
|
-0.38
|
-0.21
|
0.39
|
-0.53
|
0.43
|
|||||
|
Book Value Growth (%)
|
-45.34
|
--
|
--
|
--
|
--
|
--
|
Valuation Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
--
|
-6.54
|
-3.67
|
-13.77
|
-1.28
|
-6.85
|
|||||
|
Price / Book Value
|
2.37
|
4.96
|
1.43
|
3.66
|
1.36
|
2.17
|
|||||
|
Dividend Yield (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EV/EBITDA
|
11.56
|
-5.38
|
-1.02
|
-9.40
|
-0.34
|
-4.54
|
|||||
|
Close Price ($)
|
14.30
|
18.27
|
7.45
|
23.11
|
3.50
|
12.24
|
|||||
|
High Price ($)
|
19.11
|
19.11
|
30.99
|
24.62
|
14.41
|
21.50
|
|||||
|
Low Price ($)
|
8.96
|
3.91
|
6.90
|
2.21
|
2.19
|
6.87
|
|||||
|
Market Cap ($ Cr)
|
383.99
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
--
|
0.07
|
0.06
|
0.02
|
0.48
|
0.21
|
|||||
|
Short term debt to equity ratio
|
0.02
|
0.01
|
0.00
|
0.00
|
0.11
|
0.00
|
|||||
|
Current Ratio
|
4.50
|
8.88
|
7.81
|
5.45
|
5.00
|
10.05
|
|||||
|
Quick Ratio
|
4.46
|
8.83
|
7.77
|
5.39
|
4.92
|
9.90
|
|||||
|
Interest Coverage
|
--
|
-7,019.70
|
-9,340.43
|
-55.71
|
-31.06
|
-9.63
|
Operating Efficiency Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
3.08
|
2.08
|
1.40
|
1.75
|
37.44
|
49.69
|
|||||
|
Asset Turnover
|
0.01
|
0.08
|
0.11
|
0.17
|
0.19
|
0.21
|
|||||
|
Receivable days
|
--
|
7.32
|
5.96
|
64.72
|
149.34
|
137.48
|
|||||
|
Inventory Days
|
--
|
364.01
|
305.57
|
267.79
|
142.62
|
199.96
|
|||||
|
Payable days
|
--
|
1,963.35
|
896.64
|
489.80
|
291.81
|
272.39
|
|||||
|
Cash Conversion Cycle
|
--
|
-1,592.02
|
-585.11
|
-157.29
|
0.14
|
65.05
|